CSIMarket
 
10x Genomics Inc   (TXG)
Other Ticker:  
 
 
Price: $15.9000 $0.26 1.662%
Day's High: $16.58 Week Perf: -8.3 %
Day's Low: $ 15.65 30 Day Perf: -2.21 %
Volume (M): 3,466 52 Wk High: $ 57.90
Volume (M$): $ 55,101 52 Wk Avg: $30.79
Open: $15.70 52 Wk Low: $14.02



 Market Capitalization (Millions $) 1,920
 Shares Outstanding (Millions) 121
 Employees 1,259
 Revenues (TTM) (Millions $) 592
 Net Income (TTM) (Millions $) -251
 Cash Flow (TTM) (Millions $) 14
 Capital Exp. (TTM) (Millions $) 51

10x Genomics Inc
10x Genomics Inc.
is a life science technology company that specializes in developing and manufacturing next-generation sequencing platforms and associated software tools.
The company was founded in 2012 and is headquartered in Pleasanton, California.
The company's core technology is based on a droplet-based synthetic biology approach that enables the parallel analysis of thousands of individual cells or DNA molecules at the same time, greatly speeding up the pace of genomic research.
10x Genomics offers several products and services that leverage this technology, including single-cell and spatial gene expression solutions, immune profiling, and genome assembly.
10x Genomics' flagship product is the Chromium System, a high-throughput single-cell analysis platform that can process up to 10,000 cells in a single run.
The Chromium System enables researchers to generate high-quality gene expression data at a single-cell resolution, allowing for the identification and characterization of rare cell populations and the discovery of new biomarkers.
In addition to its research-focused offerings, 10x Genomics has also developed several clinical-grade products, including the Visium Spatial Gene Expression Solution, which enables spatial mapping of gene expression on tissue sections.
The company's products have been used in a wide range of applications, including cancer immunotherapy research, drug discovery, and agricultural genomics.
In terms of financials, 10x Genomics has experienced rapid growth since its founding, with reported revenues of $100 million in 2017, $245 million in 2018, and $375 million in 2019.
The company's stock is publicly traded on the NASDAQ stock exchange under the ticker symbol TXG.
Overall, 10x Genomics is a cutting-edge life science technology company that has developed innovative solutions for genomic research and analysis.
Its technology and products have the potential to transform the way we understand and treat complex diseases, making it a key player in the rapidly-evolving genomics market.


   Company Address: 6230 Stoneridge Mall Road Pleasanton 94588 CA
   Company Phone Number: 401-7300   Stock Exchange / Ticker: NASDAQ TXG


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BIO   -2.23%    
ILMN   -2.23%    
NAUT   -8.33%    
PACB   -3.53%    
TMO   -3.44%    
• View Complete Report
   



Stocks on the Move

10x Genomics Faces Mounting Challenges Amidst Illuminas Acquisition - A Path to Recovery Uncertain

Published Fri, Jul 12 2024 11:50 AM UTC

The genomics industry has experienced significant growth in recent years, offering innovative products for biological analysis. However, 10x Genomics now finds itself facing tough times as it grapples with declining revenues and heavy losses in key products. This downward trend has been exacerbated by competitor Illumina's recent acquisition of Fluent BioSciences, a single-c...

Products & Services

10x Genomics Unveils Groundbreaking 5,000-Plex Gene Panel for Xenium, Elevating Industr...

Published Wed, May 29 2024 8:05 PM UTC

'10x Genomics Launches 5,000-Plex Gene Panel for Xenium: A Quantum Leap in Gene Analysis'Pleasanton, Calif., May 29, 2024 - In an era defined by the rapid advancement of biotechnology, 10x Genomics, Inc. (Nasdaq: TXG), a vanguard in single-cell and spatial biology, has once again forged ahead with the launch of its revolutionary Xenium Prime 5K Pan-Tissue and Pathways gene p...

Products & Services

Unlocking the Future of Cellular Exploration: 10x Genomics Redefines Single Cell Analysis with Chromium GEM-X

Published Wed, Mar 13 2024 8:05 PM UTC

In a groundbreaking development, leading innovator in single cell and spatial biology, 10x Genomics, has announced the commercial availability of its highly anticipated Chromium GEM-X products. This next generation of their renowned single cell technology architecture promises to revolutionize the field by enhancing performance, scalability, and cost-effectiveness. With 10x ...







10x Genomics Inc's Segments
Americas    58.01 % of total Revenue
United States    55.96 % of total Revenue
Americas excluding United States    2.05 % of total Revenue
Europe Middle East and Africa    25 % of total Revenue
Asia-Pacific    17.16 % of total Revenue
China    9.93 % of total Revenue
Asia-Pacific excluding China    7.23 % of total Revenue

  10x Genomics Inc Outlook

On February 15 2024 the 10x Genomics Inc provided following guidance

10x Genomics Inc. announced its financial results for the fourth quarter and full year of 2023, with a revenue growth of 18% in the fourth quarter and 20% for t...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com